S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Biden's corruption knows no end (Ad)pixel
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Buy THIS stock before Taiwan is attacked (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Buy THIS stock before Taiwan is attacked (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Biden's corruption knows no end (Ad)pixel
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Buy THIS stock before Taiwan is attacked (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Buy THIS stock before Taiwan is attacked (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Biden's corruption knows no end (Ad)pixel
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Buy THIS stock before Taiwan is attacked (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Buy THIS stock before Taiwan is attacked (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
S&P 500   4,050.83
DOW   32,859.03
QQQ   315.68
Is SoFi Technologies a Buy in the Midst of a Banking Crisis?
Biden's corruption knows no end (Ad)pixel
3 Companies That Just Started Paying Dividends
CloudFlare's Chart Shows Bullish Moving-Average Crossover
Buy THIS stock before Taiwan is attacked (Ad)
The Squeeze Is On For EVGo, Rally To Follow 
Alibaba Just Changed The Game For Chinese Tech Conglomerates
Buy THIS stock before Taiwan is attacked (Ad)
Analysts Upgrade Ciena Corp to Strong Buy
Closing prices for crude oil, gold and other commodities
NASDAQ:FATE

Fate Therapeutics - FATE Stock Forecast, Price & News

$5.30
-0.25 (-4.50%)
(As of 03/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$5.28
$5.66
50-Day Range
$4.88
$6.87
52-Week Range
$4.02
$43.12
Volume
1.72 million shs
Average Volume
3.87 million shs
Market Capitalization
$520.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$19.44

Fate Therapeutics MarketRank™ Forecast

Analyst Rating
Hold
2.14 Rating Score
Upside/​Downside
266.7% Upside
$19.44 Price Target
Short Interest
Bearish
23.64% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.70
Upright™ Environmental Score
News Sentiment
0.01mentions of Fate Therapeutics in the last 14 days
Based on 10 Articles This Week
Insider Trading
Acquiring Shares
$698,138 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.14) to ($1.82) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

260th out of 1,009 stocks

Biological Products, Except Diagnostic Industry

48th out of 166 stocks


FATE stock logo

About Fate Therapeutics (NASDAQ:FATE) Stock

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Stock News Headlines

The gold catalyst we’ve waited for
If you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK.
ProQR (PRQR) Receives a Hold from Citigroup
15 Analysts Have This to Say About Fate Therapeutics
NK Cell Therapy Market Size and Forecast till 2031
The "King Of Quants" sees 10X potential...
Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...
Fate Therapeutics (NASDAQ:FATE) Lifted to Hold at StockNews.com
H.C. Wainwright Remains a Buy on Repare Therapeutics (RPTX)
SVB Securities Remains a Hold on F-star Therapeutics (FSTX)
See More Headlines
Receive FATE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Fate Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

FATE Company Calendar

Last Earnings
2/28/2023
Today
3/31/2023
Next Earnings (Estimated)
5/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:FATE
Fax
N/A
Employees
449
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$19.44
High Stock Price Forecast
$65.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+266.7%
Consensus Rating
Hold
Rating Score (0-4)
2.14
Research Coverage
22 Analysts

Profitability

Net Income
$-281,720,000.00
Net Margins
-292.55%
Pretax Margin
-292.55%

Debt

Sales & Book Value

Annual Sales
$96.30 million
Book Value
$4.98 per share

Miscellaneous

Free Float
81,141,000
Market Cap
$520.25 million
Optionable
Optionable
Beta
1.53

Key Executives

  • J. Scott WolchkoJ. Scott Wolchko
    President, Chief Executive Officer & Director
  • Edward J. DulacEdward J. Dulac
    Chief Financial Officer & Accounting Officer
  • Bahram ValamehrBahram Valamehr
    Chief Research & Development Officer
  • Wen Bo Wang
    Senior Vice President-Technical Operations
  • Yu Waye ChuYu Waye Chu
    Chief Medical Officer













FATE Stock - Frequently Asked Questions

Should I buy or sell Fate Therapeutics stock right now?

22 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 sell ratings, 15 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" FATE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FATE, but not buy additional shares or sell existing shares.
View FATE analyst ratings
or view top-rated stocks.

What is Fate Therapeutics' stock price forecast for 2023?

22 Wall Street analysts have issued 12-month target prices for Fate Therapeutics' shares. Their FATE share price forecasts range from $6.00 to $65.00. On average, they anticipate the company's stock price to reach $19.44 in the next year. This suggests a possible upside of 266.7% from the stock's current price.
View analysts price targets for FATE
or view top-rated stocks among Wall Street analysts.

How have FATE shares performed in 2023?

Fate Therapeutics' stock was trading at $10.09 on January 1st, 2023. Since then, FATE shares have decreased by 47.5% and is now trading at $5.30.
View the best growth stocks for 2023 here
.

Are investors shorting Fate Therapeutics?

Fate Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 21,580,000 shares, an increase of 15.6% from the February 28th total of 18,660,000 shares. Based on an average trading volume of 4,010,000 shares, the days-to-cover ratio is currently 5.4 days. Approximately 23.6% of the company's stock are sold short.
View Fate Therapeutics' Short Interest
.

When is Fate Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our FATE earnings forecast
.

How were Fate Therapeutics' earnings last quarter?

Fate Therapeutics, Inc. (NASDAQ:FATE) posted its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.86) by $0.28. The biopharmaceutical company had revenue of $44.36 million for the quarter, compared to analyst estimates of $18.41 million. Fate Therapeutics had a negative net margin of 292.55% and a negative trailing twelve-month return on equity of 50.86%. The firm's revenue was up 159.9% compared to the same quarter last year. During the same period last year, the firm posted ($0.72) EPS.

What is Scott Wolchko's approval rating as Fate Therapeutics' CEO?

2 employees have rated Fate Therapeutics Chief Executive Officer Scott Wolchko on Glassdoor.com. Scott Wolchko has an approval rating of 100% among the company's employees. This puts Scott Wolchko in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Fate Therapeutics own?
What is Fate Therapeutics' stock symbol?

Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."

Who are Fate Therapeutics' major shareholders?

Fate Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (4.34%), Millennium Management LLC (2.95%), Price T Rowe Associates Inc. MD (2.74%), Renaissance Technologies LLC (1.86%), Morgan Stanley (1.79%) and Geode Capital Management LLC (1.61%). Insiders that own company stock include Bahram Valamehr, Cindy Tahl, Daniel D Shoemaker, Edward J Dulac III, J Scott Wolchko, John Mendlein, Louis T Petrillo, Mark Plavsic, Redmile Group, Llc, Shefali Agarwal and Yu-Waye Chu.
View institutional ownership trends
.

How do I buy shares of Fate Therapeutics?

Shares of FATE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Fate Therapeutics' stock price today?

One share of FATE stock can currently be purchased for approximately $5.30.

How much money does Fate Therapeutics make?

Fate Therapeutics (NASDAQ:FATE) has a market capitalization of $520.25 million and generates $96.30 million in revenue each year. The biopharmaceutical company earns $-281,720,000.00 in net income (profit) each year or ($2.91) on an earnings per share basis.

How many employees does Fate Therapeutics have?

The company employs 449 workers across the globe.

How can I contact Fate Therapeutics?

Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The official website for the company is www.fatetherapeutics.com. The biopharmaceutical company can be reached via phone at (858) 875-1800 or via email at christina@sternir.com.

This page (NASDAQ:FATE) was last updated on 3/31/2023 by MarketBeat.com Staff